linjc16/ctgov huggingface dataset:
Structural Imaging Assisted Retinal Fluorescence Lifetime Imager (STARFLI)

Study Overview
=================
Brief Summary
-----------------
To investigate the feasibility of a combined OCT/FLIM device

Detailed Description
-----------------
To investigate the feasibility of a combined Optical coherence tomography/ Fluorescence Lifetime Measurement (OCT/FLIM) device.

Official Title
-----------------
Structural Imaging Assisted Retinal Fluorescence Lifetime Imager (STARFLI) Using a High-speed Fluorescence Lifetime Measurement Scheme

Conditions
-----------------
Retinal Disease

Intervention / Treatment
-----------------
* Device: OCT/FLIM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject must be willing to give written informed consent Age: Patients and Probands 18 years or greater Both eyes will be assessed in the study Exclusion Criteria: Patients not willing or able to sign informed consent Patients younger than 18 years Patients with epilepsy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: OCT/FLIM|OCT/FLIM imaging of the retina|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility of device | We will organize and perform an observational study with the prototype OCT+FLIM device and contribute the acquired OCT/FLIM datasets from eyes of different age and status of the crystalline lens. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To provide two key technology aspects of the project: | A. The first will be to bring forward a novel registration strategy for calibrated OCT and FLIM modalities, so that these can be used in conjunction. B. The second will be to develop an image calibration and normalization method using the measured lens fluorescence lifetime and possibly also structural (OCT) information on lens and retina, so that data acquired by the device can be used across different patients in a consistent way. | 1 year |
International Registry of Congenital Portosystemic Shunt (IRCPSS)

Study Overview
=================
Brief Summary
-----------------
Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications. CPSS is venous anomaly in which blood coming from the intestines only partially passes through the liver. This leads to the accumulation of potentially toxic factors that cause systemic effects. Complications vary among the individuals, and currently, it is challenging to predict which individuals will develop severe complications. The IRCPSS registry is established with the aim of centralizing detailed clinical follow-up and biological information from participants around the world who suffer from Congenital Portosystemic Shunt (CPSS). A multidisciplinary consortium of experts is collaborating to enhance our understanding of the prevalence, natural history, individual risks, and physiopathology of the disease through the IRCPSS registry.

Official Title
-----------------
International Registry of Congenital Portosystemic Shunts (IRCPSS) - A Multi-centre, Retrospective and Prospective Registry of Neonates, Children and Adults With Congenital Portosystemic Shunts

Conditions
-----------------
Congenital Porto-Systemic Shunt (CPSS)

Intervention / Treatment
-----------------
* Procedure: Shunt Closure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individual with CPSS Exclusion Criteria: Secondary shunt without evidence of congenital shunt

Ages Eligible for Study
-----------------
Minimum Age: 1 Day

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neonate, Children, Adult with CPSS<br> | Procedure: Shunt Closure<br>* Consist in spontaneous, surgical or interventional closure of the shunt. Depending on context, surgical intervention may also be transplantation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numbers of patients with spontaneous shunt closure |  | 3; 6; 12; 24 months | 
| Number of patients developing one or more complications |  | 5; 10; 20 years | 
| Number of patients undergoing preemptive closure |  | 6; 12; 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hyperandrogenism, Hepatic Encephalopathy, Hyperammonemia, shunt, portosystemic, portasystemic, porto-systemic, porta-systemic, registry, liver, rare disease, Abernethy malformation, vascular malformation, Hypertension, Pulmonary, Hepatopulmonary Syndrome, Liver Neoplasms, hyperinsulinemic, hypoglycemia, hyperinsulinism, Insulin resistance
Effect of Balneotherapy and Physiotherapy Treatment in Female Infertility: a Retrospective Study

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to assess the effect of complex balneotherapy and physiotherapy treatment among infertile women treated in the Harkany Thermal Rehabilitation Center between July 01, 2007 and December 31, 2021. The main questions it aims to answer are: To what extent can the complex balneotherapy and physiotherapy treatment be an effective additional therapy in female infertility? What are the clinical changes behind infertility that can be helped by the complex balneotherapy and physiotherapy treatment? Participants will be asked to answer a questionnaire that we have prepared.

Official Title
-----------------
Combined Effect of Balneotherapy and Physiotherapy Treatment in Female Infertility at Harkany Thermal Rehabilitation Centre: a Retrospective Study

Conditions
-----------------
Infertility, Female

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female gender Diagnosed primary or secondary infertility Exclusion Criteria: Lack of cooperation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| successful conception | Assessing with questionnaire. The participants are asked to answer the question whether they had a positive pregnancy test within 1 year after the complex balneotherapy and physiotherapy treatment at the Harkany Thermal Rehabilitation Center. | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| successful delivery | Assessing with questionnaire. We ask the participants, if they managed to get pregnant within 1 year after the complex balneo and physiotherapy treatment to answer the question about what the outcome of their pregnancy was (for example: childbirth, miscarriage, stillbirth, etc.). | 12 months | 
| the effect of the treatments on successful conception in different causes of infertility | Assessing with questionnaire and statistical analysis. Based on the answers to the questionnaire, we will use statistical analysis to investigate the proportion of successful pregnancies after the complex balneotherapy and physiotherapy treatment in the case of the different pathologies underlying infertility. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Balneotherapy, Physiotherapy, Questionnaire, Infertility
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients

Study Overview
=================
Brief Summary
-----------------
The study will determine if Therapeutic Plasma Exchange removes RNA biomarkers associated with Alzheimer's Disease and how quickly those biomarkers reappear after treatment.

Detailed Description
-----------------
Participants with a diagnosis of Alzheimer's or Mild Cognitive Impairment will undergo therapeutic plasma exchange as part of their treatment for the disease as per the AMBAR Trial protocol. Patients will undergo one non-invasive tests to assess their microvascular system and complete one online test to assess the degree of cognitive impairment. Patients will have their blood drawn pre-plasma exchange, immediately post plasma exchange and repeated assessments and blood draws at seven day intervals post plasma exchange ending on the twenty-eighth day after the plasma exchange. Their blood will be analyzed by FBB Biomed to identify the presence of unique RNA biomarkers associated with Alzheimer's disease and determine how quickly they regenerate.

Official Title
-----------------
Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients

Conditions
-----------------
Alzheimer Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is scheduled to undergo their first TPE Procedure for a diagnosis of Alzheimer's Disease or previous mental/cognitive impairment Mentally capable of understanding and completing informed consent for the study. Exclusion Criteria: Subject is unable or failed to return/provide blood specimen on days seven (7), fourteen (14) , twenty-one (21), and twenty-eight (28) (plus or minus 1 day on follow up draws) post plasma exchange Subject is unable to provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To ascertain if Therapeutic Plasma Exchange (TPE) reduces the presence of RNA biomarkers in a small sample of Alzheimer's patients. | Measurement of RNA Biomarkers inside the participants blood stream | 28 days |
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
The objective of the present registry is the creation of a prospective registry collecting clinico-pathological and genomic data, along with survival outcomes, of individuals diagnosed with PDAC at or before the age of 55 years old. This registry is intended with the aim of using collected data for future clinical trials, both prospective and retrospective.

Official Title
-----------------
Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer

Conditions
-----------------
PDAC - Pancreatic Ductal Adenocarcinoma

Intervention / Treatment
-----------------
* Other: Register


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≤55 years old at the time of diagnosis of pancreatic cancer Age ≥ 18 years Written informed consent obtained. Exclusion Criteria: Any pancreatic neoplasm other than pancreatic cancer (e.g. cholangiocarcinoma, ampullary cancer,duodenal cancer, non-invasive mucinous cystic neoplasm, pancreatic intra-epithelial neoplasia 1 and 2, non-invasive intraductal papillary mucinous neoplasm, serous cystic neoplasm, pseudo papillary solid tumor, neuroendocrine tumor) Absence of informed consent. Age < 18 years or > 55 years old at the time of diagnosis of pancreatic cancer

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Register|Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Register of young PDAC patients | Prospective collection of epidemiological, clinical, and pathological data of patients diagnosed with early-onset pancreatic cancer (EO-PDAC) - namely, individuals who have received a diagnosis of pancreatic cancer before, or at, the age of 55 years old. | 30 years |
New Diagnostic Markers In Dignosis Of Complicated Appendix

Study Overview
=================
Brief Summary
-----------------
Most common cause of acute abdomen is acute appendicitis delay dignosis of acute appendicitis lead to complications as perforation this study examined efficacy of hyperbilirubinemia&hyponatremia as indicator of complicated appendicitis

Official Title
-----------------
New Diagnostic Markers In Dignosis Of Complicated Appendix

Conditions
-----------------
Complicated Appendicitis

Intervention / Treatment
-----------------
* Diagnostic Test: Bilirubin level sodium level c reactive protein level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patient admitted for acute appendicitis underwent surgery and post operativly confirmed histopathology of acute appendicitis Exclusion Criteria: patient with liver disease Liver transplantation Chronic alcoholism Congental biliary disease Pregnancy Appendicular neoplasm Hemolytic disease Hepatocellular carcinoma

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Bilirubin level sodium level c reactive protein level|detect level of bilirubin,sodium &c-reactive protein as indicator of complicated appendicitis|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Level of bilirubin in acute appendicitis |  | 6 months | 
| Level of sodium in acute appendicitis |  | 6 months | 
| Level of c-reactive proteins in acute appendicitis |  | 6 months |
The Use of Stromal Vascular Fraction for Knee Arthrosis

Study Overview
=================
Brief Summary
-----------------
A trial to investigate the safety and efficacy of SVF for the treatment of knee arthrosis. Patients will undergo a single liposuction to obtain the SVF. The SVF will then be isolated and frozen in our laboratory. The SVF will then be injected up to 2 times into the fat pad of the patient's knee.

Detailed Description
-----------------
Stromal Vascular Fraction (SVF) from adipose tissue is increasingly being used in the clinic for a variety of conditions (skin disorders, joint pain, etc.). SVF is a collective term for cells that can be obtained from liposuction fat. These cells can be separated from the fat by mechanical processing of the liposuction fat combined with an additional centrifugation. Despite the fact that enough SVF can be isolated after such a liposuction for multiple treatments (>3), our research group has found a way to safely freeze SVF without significant loss of SVF cells. In this way, a patient would only have to undergo one liposuction and associated anesthesia to be able to obtain multiple SVF treatments.

Official Title
-----------------
Gebruik Van Stromale Vasculaire Fractie Uit Vetweefsel na Invriezing Voor Knie Arthrose

Conditions
-----------------
Knee Arthrosis

Intervention / Treatment
-----------------
* Procedure: Injection of SVF in fat pad of the knee


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Legal capacity Osteochondral lesions Inflammatory complaints (Peri)tendinitis or tendinopathies and ligamentous injuries Impingement complaints Arthrofibrosis Anterior knee pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Injection of SVF in fat pad of the knee|Knee fat pad injection with SVF at orthopaedics/physical medicine outpatient clinic|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the safety of SVF injections after cryo preservation | The patient will complete the KOOS questionnaire (Knee Injury and Osteoarthritis Outcome Score) on several timepoints. | 1 year |
PocDoc Lipids Usability Study for Self-test Use

Study Overview
=================
Brief Summary
-----------------
This study seeks to expand the approved indication of use for a UKCA approved IVD device. PocDoc lipids is approved for professional use to measure the levels of lipids in a fingerprick blood samples. This study will investigate the usability of the device by untrained lay people in order to expand the device's utility to the self-test setting.

Official Title
-----------------
PocDoc Lipids Usability Study for Self-test Use

Conditions
-----------------
Hyperlipidemias

Intervention / Treatment
-----------------
* Diagnostic Test: PocDoc


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent form Subjects are legally competent and capable to understand character, meaning and consequences of the study Subjects own an approved mobile device (these will be available at the time of the study on the PocDoc website and a link will be contained in the PIS) Exclusion Criteria: Being unable to give informed consent < 18 years or > 85 years Legally incompetent Language barriers potentially compromising an adequate compliance with study procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PocDoc<br>All participants given PocDoc device | Diagnostic Test: PocDoc<br>* Point of care digital lipid test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Usability | The usability study will pass our acceptance criteria if 95% of the users are able to successfully conduct a PocDoc lipid test, obtaining a result. The PocDoc lipid test is a rapid 5-marker lipid test in lateral flow format that uses a smartphone application to analyse and display the result. Usability is defined as the ability of an individual to navigate the mobile application steps to conduct the rapid lateral flow test, to take a picture of the image and to navigate to the results page of the application to see their results. A successful test is one where the individual successfully completes all steps and gets their result. | Day 1 - one single test done at one timepoint |
Combined Chromium With Letrozole Versus Letrozole Only in Induction of Ovulation in Patients With Polycystic Ovary Syndrome

Study Overview
=================
Brief Summary
-----------------
Combined letrozole with chromium versus letrozole only in induction of ovulation in polycystic ovary syndrome

Detailed Description
-----------------
Randomized controlled trial

Official Title
-----------------
Letrozole and Chromium

Conditions
-----------------
Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Drug: Letrozole with chromium


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female patients aged from 18 to 35 years Anovulatory cycles Pcos Exclusion Criteria: female patients aged more than 35years Male factor of infertility Other factors of infertility than pcos

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Letrozole<br>Letrozole versus letrozole with chromium | Drug: Letrozole with chromium<br>* Letrozole versus letrozole with chromium<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of letrozole | efficacy of letrozole with chromium in improving induction of ovulation | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Miscarriage rate | Incidence of OHSS | 12 months |